B. Riley Weighs in on Harrow’s FY2024 Earnings (NASDAQ:HROW)

Harrow, Inc. (NASDAQ:HROW) – B. Riley dropped their FY2024 earnings estimates for Harrow in a report released on Wednesday, December 4th. B. Riley analyst M. Mamtani now anticipates that the company will post earnings per share of ($0.53) for the year, down from their prior estimate of $0.09. B. Riley currently has a “Buy” rating and a $69.00 price objective on the stock. The consensus estimate for Harrow’s current full-year earnings is $0.09 per share. B. Riley also issued estimates for Harrow’s Q4 2024 earnings at $0.06 EPS, FY2025 earnings at $0.99 EPS, FY2026 earnings at $3.07 EPS and FY2027 earnings at $5.28 EPS.

HROW has been the subject of several other reports. Lake Street Capital raised their price objective on Harrow from $45.00 to $55.00 and gave the stock a “buy” rating in a research note on Friday, October 4th. Craig Hallum raised their price target on shares of Harrow from $45.00 to $65.00 and gave the stock a “buy” rating in a research report on Friday, October 4th.

Harrow Stock Performance

Shares of HROW stock opened at $39.32 on Friday. The company has a debt-to-equity ratio of 3.23, a current ratio of 1.55 and a quick ratio of 1.44. The business has a fifty day moving average of $47.09 and a 200 day moving average of $35.23. The firm has a market capitalization of $1.40 billion, a price-to-earnings ratio of -41.83 and a beta of 0.69. Harrow has a 1 year low of $9.13 and a 1 year high of $59.23.

Institutional Trading of Harrow

A number of hedge funds have recently modified their holdings of the stock. Quest Partners LLC acquired a new position in Harrow in the third quarter valued at approximately $29,000. nVerses Capital LLC acquired a new position in shares of Harrow in the 2nd quarter valued at $33,000. Allspring Global Investments Holdings LLC lifted its stake in shares of Harrow by 2,730.7% in the 2nd quarter. Allspring Global Investments Holdings LLC now owns 2,123 shares of the company’s stock valued at $44,000 after purchasing an additional 2,048 shares during the period. Mirae Asset Global Investments Co. Ltd. boosted its holdings in Harrow by 21.5% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,283 shares of the company’s stock worth $57,000 after buying an additional 227 shares in the last quarter. Finally, Hills Bank & Trust Co acquired a new stake in Harrow during the third quarter valued at $107,000. Hedge funds and other institutional investors own 72.76% of the company’s stock.

About Harrow

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.